Breaking news: On November 9th, 2020, the world got a glimmer of hope when the pharmaceutical giant, Pfizer announced that it's COVID 19 vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.
- The vaccine currently being developed and studied by Pfizer is an RNA vaccine that targets the spike protein, the spiky protrusion on the SARS-CoV-2 virus that allows the virus to attach to and invade human cells, initiating infection.
- An RNA vaccine basically consists of an mRNA strand artificially created that codes for a disease-specific antigen which when injected in to the human or animal body, creates an antibody response.
- In fact, all of the vaccines being developed by major manufacturers working with Operation Warp Speed, the U.S. government effort to fast-track vaccines, target the spike protein.
The preliminary analysis evaluated 94 confirmed cases of COVID-19 in trial participants. The study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected. See full press release